Inflammation and oxidative stress in diabetic kidney disease: the targets for SGLT2 inhibitors and GLP-1 receptor agonists

A Winiarska, M Knysak, K Nabrdalik… - International Journal of …, 2021 - mdpi.com
The incidence of type 2 diabetes (T2D) has been increasing worldwide, and diabetic kidney
disease (DKD) remains one of the leading long-term complications of T2D. Several lines of …

The impact of SGLT2 inhibitors on inflammation: A systematic review and meta-analysis of studies in rodents

P Theofilis, M Sagris, E Oikonomou… - International …, 2022 - Elsevier
Background Inhibition of sodium-glucose cotransporter-2 (SGLT2) has received remarkable
attention due to the beneficial effects observed in diabetes mellitus, heart failure, and kidney …

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial

MN Kosiborod, R Esterline, RHM Furtado… - The lancet Diabetes & …, 2021 - thelancet.com
Background COVID-19 can lead to multiorgan failure. Dapagliflozin, a SGLT2 inhibitor, has
significant protective benefits for the heart and kidney. We aimed to see whether this agent …

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

HJL Heerspink, CD Sjöström, N Jongs… - European heart …, 2021 - academic.oup.com
Aims Mortality rates from chronic kidney disease (CKD) have increased in the last decade. In
this pre-specified analysis of the DAPA-CKD trial, we determined the effects of dapagliflozin …

Comparative Effectiveness of Sodium–Glucose Cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-Primary Emergency Department Visits and …

N McCormick, C Yokose, J Wei, N Lu… - Annals of Internal …, 2023 - acpjournals.org
Background: Sodium–glucose cotransporter-2 inhibitors (SGLT2is) decrease serum urate
levels, but whether this translates into prevention of recurrent flares among patients with …

Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID‐19: Design and rationale for the …

M Kosiborod, O Berwanger, GG Koch… - Diabetes, Obesity …, 2021 - Wiley Online Library
Abstract Aims Coronavirus disease 2019 (COVID‐19) is caused by a novel severe acute
respiratory syndrome coronavirus 2. It can lead to multiorgan failure, including respiratory …

Empagliflozin and uric acid metabolism in diabetes: a post hoc analysis of the EMPA‐REG OUTCOME trial

JP Ferreira, SE Inzucchi, M Mattheus… - Diabetes, Obesity …, 2022 - Wiley Online Library
Aim To evaluate the effect of empagliflozin on uric acid (UA) levels, antigout medication and
gout episodes in the EMPA‐REG OUTCOME trial (NCT01131676). Materials and methods A …

Tubular cell glucose metabolism shift during acute and chronic injuries

A Faivre, T Verissimo, H Auwerx, D Legouis… - Frontiers in …, 2021 - frontiersin.org
Acute and chronic kidney disease are responsible for large healthcare costs worldwide.
During injury, kidney metabolism undergoes profound modifications in order to adapt to …

[HTML][HTML] Exogenous ketone ester administration attenuates systemic inflammation and reduces organ damage in a lipopolysaccharide model of sepsis

S Soni, MD Martens, S Takahara, HL Silver… - … et Biophysica Acta (BBA …, 2022 - Elsevier
Aims Sepsis is a life-threatening condition of organ dysfunction caused by dysregulated
inflammation which predisposes patients to developing cardiovascular disease. The ketone …

Sodium-glucose transport protein 2 inhibitor use for type 2 diabetes and the incidence of acute kidney injury in Taiwan

MC Chung, PH Hung, PJ Hsiao, LY Wu… - JAMA Network …, 2023 - jamanetwork.com
Importance The association between sodium-glucose transport protein 2 inhibitor (SGLT2i)
use and the incidence of acute kidney injury (AKI) remains controversial. The benefits of …